How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?
HCT116 colorectal cancer cells, anti-PD-L1, immunotherapy, eriodictyol, interleukin-2 production
Abstract
This paper aims to explore the effect of anti-PD-L1 antibody on HCT116 colorectal cancer cells and their corresponding xenografts in a mouse model. The central hypothesis is that increasing the concentration of anti-PD-L1 antibodies and the duration of treatment will result in a reduction in cell viability, a reduction in tumour size, and an enhancement in T cell activation. The viability of the cells was evaluated through the MTT method, which quantifies metabolic activity as an indicator of cellular health. The size of the tumour was determined by weighing the excised tumours. An enzyme-linked immunosorbent assay (ELISA) was employed to evaluate T cell activation by quantifying interleukin-2 (IL-2) production. In order to establish a framework for comparison, eriodictyol, a known PD-L1 inhibitor, was used as a positive control, while an unrelated antibody served as a negative control. According to the research, the preliminary study results indicated that higher concentrations and prolonged exposure to anti-PD-L1 antibodies significantly reduced HCT116 cell viability and tumour weight, while increasing IL-2 levels, which suggests enhanced T cell activation. These results indicate a strong correlation between anti-PD-L1 antibody therapy and immune system involvement in the context of colorectal cancer. The objective of this study was to emphasise the potential of anti-PD-L1 therapy in stimulating an immune response to malignant growths. Furthermore, the necessity for optimising treatment parameters is investigated and disccussed, including dosage and duration, in order to maximise the efficacy of cancer immunotherapy. This could facilitate the use of immune checkpoint inhibitors in clinical settings, potentially improving outcomes for patients with colorectal cancer and other tumour types.
